The facility will increase the manufacturing and delivery capacity of Yescarta in the European market. The drug is also being studied for the treatment of indolent non-Hodgkin’s lymphoma (NHL) and first-line DLBCL. The drug received marketing approval in the European Union in August 2018, indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) in adult patients. Kite Pharma will manufacture its cancer immunotherapy products in the facility, including the US Food and Drug Administration (FDA)-approved Yescarta ® (axicabtagene ciloleucel).
“The manufacturing facility will be an addition to Kite Pharma’s manufacturing network in the US, which includes the California and Maryland sites.” The facility features Grade A sustainable design and complies with the Building Research Establishment Environmental Assessment Method (BREEAM) Excellent standard, which helps in reducing the carbon footprint for the company. Kite Pharma leased 117,000ft² of space in SEGRO Park from SEGRO for the development of the manufacturing plant. Kite Pharma’s biopharmaceutical manufacturing facility details The site is also well connected by road via A4 to The Hague and Rotterdam, as well as the extended A5, which connects to the port. The proximity of the facility to Amsterdam Schiphol Airport and the Amsterdam metropole provides an opportunity for business growth in the future. SEGRO Park is a 400,000m² flexible site developed by SEGRO, a real estate investment trust based in the UK, which can be divided into multi or single-tenant spaces for the accommodation of various types of industries including pharmaceutical, manufacturing, logistics and food and beverage. The manufacturing facility is located at the SEGRO Park Amsterdam Airport at Tufsteen 1 in Hoofddorp, North Holland province, Netherlands. Kite Pharma’s biopharmaceutical manufacturing facility location The plant is expected to be fully operational by 2020, employing more than 300 people.
0 kommentar(er)
